Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAznar Ruiz de Alegria, Maria Luisa
dc.contributor.authorMoreno, María Milagros
dc.contributor.authorEspasa Soley, Mateu
dc.contributor.authorSulleiro Igual, Elena
dc.contributor.authorBocanegra García, Maria Cristina
dc.contributor.authorGil Olivas, Eva
dc.contributor.authorEscartin Huesca, Carlos
dc.contributor.authorVegue-Collado, Josep
dc.contributor.authorVivas-Cano, Maria-Carmen
dc.contributor.authorPumarola Suñé, Tomàs
dc.contributor.authorTórtola Fernández, Mª Teresa
dc.contributor.authorRando Segura, Ariadna
dc.contributor.authorMolina Romero, Israel
dc.date.accessioned2022-05-03T12:40:50Z
dc.date.available2022-05-03T12:40:50Z
dc.date.issued2021-10-12
dc.identifier.citationRando-Segura A, Aznar ML, Moreno MM, Espasa Soley M, Sulleiro Igual E, Bocanegra Garcia C, et al. Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola. BMC Infect Dis. 2021 Oct 12;21:1056.
dc.identifier.issn1471-2334
dc.identifier.urihttps://hdl.handle.net/11351/7463
dc.descriptionAngola; Rifampicin; rpoB mutations
dc.description.abstractBackground The importance of Mycobacterium tuberculosis strains with disputed rpoB mutations remains to be defined. This study aimed to assess the frequency and types of rpoB mutations in M. tuberculosis isolates from Cubal, Angola, a country with a high incidence of tuberculosis. Methods All isolates included (n = 308) were analyzed using phenotypic drug susceptibility testing and GenoType MTBDRplus assay. DNA sequencing of the rpoB gene and determination of rifampicin MIC by macrodilution method were additionally performed on isolates yielding discordant results (n = 12) and those in which the mutation detected was not characterized (n = 8). Results In total, 85.1% (74/87) of rifampicin-resistant strains had undisputed rpoB mutations -S450L (49), D435V (15), H445D (3), H445Y (2), Q432ins (1), L449M plus S450F (1), S450F (1), S450W (1) and S450Y (1)-; 10.3% (9/87) had disputed rpoB mutations—L430P plus S493L (1), N437del (1), H445L (3), D435Y (2), L452P (2)-, 2.3% (2.3%) showed no rpoB mutations and 2.3% (2/87) showed heteroresistance—D435Y plus L452P and L430P plus S493L-. Conclusion Disputed rpoB mutations were common, occurring in 10.3% of rifampicin resistant isolates. Current phenotyping techniques may be unable to detect this resistance pattern. To increase their sensitivity, a lower concentration of RIF could be used in these tests or alternatively, rpoB mutations could be screened and characterized in all M. tuberculosis strains.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesBMC Infectious Diseases;21
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectTuberculosi - Epidemiologia
dc.subjectRNA-polimerases
dc.subjectTests de sensibilitat microbiològica
dc.subject.meshTuberculosis
dc.subject.meshDNA-Directed RNA Polymerases
dc.subject.meshMicrobial Sensitivity Tests
dc.titleMolecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12879-021-06763-8
dc.subject.decstuberculosis
dc.subject.decsARN polimerasas dirigidas por ADN
dc.subject.decspruebas de sensibilidad microbiana
dc.relation.publishversionhttps://doi.org/10.1186/s12879-021-06763-8
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rando-Segura A, Espasa Soley M, Sulleiro Igual E, Escartin Huesca C, Vegue Collado J, Vivas Cano MC, Pumarola Suñe T, Tórtola Fernández MT] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Aznar ML, Bocanegra Garcia C, Gil Olivas E] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Hospital Nossa Senhora da Paz, Cubal, Angola. [Moreno MM] Hospital Nossa Senhora da Paz, Cubal, Angola. [Molina Romero I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid34641802
dc.identifier.wos000706724400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record